Kodiak Sciences INC 10-Q quarterly reports

Kodiak Sciences reported substantial net losses and negative cash flows, raising significant doubt about its ability to continue as a going concern, despite ongoing clinical trial progress for its retinal disease therapies.

Kodiak Sciences reported increased net losses and substantial doubt about its ability to continue as a going concern, despite ongoing progress in its late-stage retinal disease clinical programs.

Kodiak Sciences reports a net loss of $57.5 million for Q1 2025 and provides updates on its tarcocimab, KSI-501, and KSI-101 clinical programs.

Kodiak Sciences reported its financial results for the third quarter of 2024, highlighting ongoing clinical trials and advancements in its pipeline.

Kodiak Sciences reported its second quarter 2024 financial results, highlighting progress in its clinical programs and leadership changes.

Kodiak Sciences reported a net loss of $43.0 million for the first quarter of 2024, while advancing its clinical programs and manufacturing capabilities.